News Doubts over AbbVie PARP inhibitor after double trial failure Veliparib fails in two phase 3 trials.
News AZ's Lynparza impresses with new ovarian cancer data UK firm lays down the gauntlet in the PARP inhibitor battle.
News UK biotech Astex celebrates as Novartis breast cancer drug a... Cambridge firm played key role in discovery of potential blockbuster Kisqali.
News Servier and Pfizer begin trials for off-the-shelf T-cell can... Companies hope to challenge traiblazers Novartis and Kite.
News Brexit could deny children access to cancer drug trials Experts call for shake-up of EU regulation.
News US drug revenues far exceed R&D spend - report Analysis questions industry's rationale for high US prices.
R&D LSX 2024 - Luba Greenwood and Hakim Yadi High-profile digital health investor Luba Greenwood recently announced that she’s joined as Chair of the Board at Closed Loop Medicine, a company applying machine learning to precision drug
Sales & Marketing Sponsored Global reach, personal touch: Mastering customer engagement ... In today's interconnected pharma market, the ability to scale engagement across borders is essential for survival and growth.